Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin for Left Ventricular Function in Acute Myocardial Infarction
NCT00449488Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2007
- Primary completion
- Oct 2009
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epoetin alfa in myocardial infarction (MI) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Left ventricular ejection fraction at 6 weeks. Started Jan 2007; status: completed.
02
Drugs
epoetin alfa
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT00449488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00449488.